Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
August 15, 2012

Genocea begins Phase I/IIa HSV-2 investigational vaccine study

Genocea Biosciences has begun Phase I/IIa clinical study of GEN-003, a therapeutic vaccine candidate for herpes simplex virus-2 (HSV-2).

herpes simplex virus

Genocea Biosciences has begun Phase I/IIa clinical study of GEN-003, a therapeutic vaccine candidate for herpes simplex virus-2 (HSV-2).

GEN-003 is an investigational vaccine designed to stimulate T and B cell immune responses to potentially reduce the frequency and severity of clinical outbreaks associated with moderate-to-severe HSV-2 infection.

The vaccine is comprised of two proteins, ICP4 and gD2, as well as Matrix M, a proprietary adjuvant from Isconova.

Genocea chief medical officer Dr Seth Hetherington said T cell immunity is increasingly seen as essential to protecting against many infectious diseases.

"Our platform enables us to comprehensively evaluate potential T cell antigens with a speed not possible through traditional methods," Dr Hetherington said.

The double-blind, dose escalation clinical trial will enrol approximately 150 volunteers with moderate-to-severe HSV-2 who are otherwise healthy.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The placebo-controlled study is designed to evaluate the safety and tolerability of GEN-003 and its ability to stimulate the immune system. It will also determine the impact of the vaccine upon viral shedding, which is considered to be a marker of disease recurrence and transmission.

The preclinical studies of GEN-003 demonstrated the ability of the candidate vaccine to bring out strong and lasting B and T cell immune responses, and showed a significant impact on the severity and duration of the disease.

Image: Transmission electron micrograph of herpes simplex virus. Photo: CDC/Dr. Erskine Palmer.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy